CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce an antitumor immune response via their rapid produ...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Lisa A., Lameris, Roeland, de Gruijl, Tanja D., van der Vliet, Hans J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036112/
https://www.ncbi.nlm.nih.gov/pubmed/30013569
http://dx.doi.org/10.3389/fimmu.2018.01519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036112/
https://www.ncbi.nlm.nih.gov/pubmed/30013569
http://dx.doi.org/10.3389/fimmu.2018.01519

Ejemplares similares